Evidence map›Paper›PMID 35354306›Full record

Trial reportCirculation2022

Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.

Barry A Borlaug, John Blair, Martin W Bergmann, Heiko Bugger, Dan Burkhoff, Leonhard Bruch, David S Celermajer, Brian Claggett, John G F Cleland, Donald E Cutlip and 27 more

Erratum issued Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05425459 (Re-Evaluation of the Corvia Atrial Shunt Device in a Precision Medicine Trial to Determine Efficacy in Mildly Reduced or Preserved Ejection Fraction), which is not on this map. Cited by 51 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 3 pooled it
18.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05425459 naactive not recruitingnot on this map

Re-Evaluation of the Corvia Atrial Shunt Device in a Precision Medicine Trial to Determine Efficacy in Mildly Reduced or Preserved Ejection Fraction (EF) Heart Failure (Protocol #2201)

TypeinterventionalSponsorCorvia MedicalRan2022 to 2031Enrolled750ConditionsHeart Failure, Heart Failure, DiastolicArmsCorvia Atrial Shunt System / IASD System II, Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 116 citations in OpenAlex.

  1. Pooled it
  2. Implanted haemodynamic telemonitoring devices to guide management of heart failure: a review and meta-analysis of randomised trials.Clinical research in cardiology : official journal of the German Cardiac Society · 2023
    Pooled it
  3. Guideline
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Observational
  16. Therapeutic Manipulation of the Atrial Septum: Tearing Down the Wall.Journal of the Society for Cardiovascular Angiography & Interventions · 2026
    Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

37 authors at 20 institutions in 10 countries.

Barry A BorlaugDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).ORCID 0000-0001-9375-0596
John BlairUniversity of Chicago (J.B.).
Martin W BergmannCardiologicum Hamburg, Germany (M.W.B.).
Heiko BuggerMedical University of Graz, Austria (H.B.).
Dan BurkhoffCardiovascular Research Foundation, New York, NY (D.B., M.B.L.).ORCID 0000-0003-3995-2466
Leonhard BruchBG Klinikum Unfallkrankenhaus, Berlin, Germany (L.B.).ORCID 0000-0002-7295-5805
David S CelermajerRoyal Prince Alfred Hospital, The University of Sydney, Australia (D.S.C.).ORCID 0000-0001-7640-0439
Brian ClaggettBrigham and Women's Hospital, Boston, MA (B.C., S.D.S.).ORCID 0000-0002-4215-9218
John G F ClelandRobertson Centre for Biostatistics and Glasgow Clinical Trials Unit, Institute of Health and Wellbeing, United Kingdom (J.G.F.C.).
Donald E CutlipBaim Clinical Research Institute, Boston, MA (D.E.C., Q.G.).ORCID 0000-0002-7583-9893
Ira DauberSouth Denver Cardiology Associates/Centura Health, CO (I.D.).
Jean-Christophe EicherCHU de Dijon-Hôpital Bocage Central, Dijon, France (J.-C.E.).ORCID 0000-0002-2549-679X
Qi GaoBaim Clinical Research Institute, Boston, MA (D.E.C., Q.G.).
Thomas M GorterUniversity of Groningen, University Medical Center Groningen, The Netherlands (T.M.G., D.J.V.V.).ORCID 0000-0001-5000-8359
Finn GustafssonRigshospitalet, University of Copenhagen, Denmark (F.G.).ORCID 0000-0003-2144-341X
Chris HaywardSt Vincents Hospital Sydney, Australia (C.H.).ORCID 0000-0003-4036-1890
Jan van der HeydenAZ Sint-Jan Brugge-Oostende, Bruges, Belgium (J.v.d.H.).
Gerd HasenfußHeart Center, University Medical Center, Göttingen, Germany (G.H.).
Scott L HummelUniversity of Michigan, Ann Harbor (S.L.H.).ORCID 0000-0002-0924-3135
David M KayeAlfred Hospital, Melbourne, Australia (D.M.K.).ORCID 0000-0003-4058-0372
Jan KomtebeddeCorvia Medical Inc, Tewksbury, MA (J.K.).
Joseph M MassaroBoston University School of Public Health, MA (J.M.M.).ORCID 0000-0002-2682-4812
Jeremy A MazurekHospital of the University of Pennsylvania, Philadelphia (J.A.M., F.E.S.).
Scott McKenziePrince Charles Hospital, Brisbane, Australia (S.M.).ORCID 0000-0002-1129-2905
Shamir R MehtaMcMaster University and Hamilton Health Sciences, Hamilton, Canada (S.R.M.).ORCID 0000-0003-3258-949X
Mark C PetrieUniversity of Glasgow, Scotland (M.C. Petrie).ORCID 0000-0002-6333-9496
Marco C PostDepartments of Cardiology, St Antonius Hospital Nieuwegein and University Medical Center Utrecht, the Netherlands (M.C. Post).
Ajith NairBaylor College of Medicine, Houston, TX (A.N.).
Andreas RiethKerckhoff Heart and Thoraxcenter, Bad Nauheim, Germany (A.R.).ORCID 0000-0001-8944-1192
Frank E SilvestryHospital of the University of Pennsylvania, Philadelphia (J.A.M., F.E.S.).
Scott D SolomonBrigham and Women's Hospital, Boston, MA (B.C., S.D.S.).ORCID 0000-0003-3698-9597
Jean-Noël Trochul'Institut du Thorax, CHU Nantes, Nantes Université, CNRS, INSERM, Nantes, France (J.-N.T.).ORCID 0000-0003-4742-281X
Dirk J Van VeldhuisenUniversity of Groningen, University Medical Center Groningen, The Netherlands (T.M.G., D.J.V.V.).
Ralf WestenfeldDivision of Cardiology, Pulmonology, and Vascular Medicine Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany (R.W.).
Martin B LeonCardiovascular Research Foundation, New York, NY (D.B., M.B.L.).
Sanjiv J ShahNorthwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.).ORCID 0000-0002-5655-8201
REDUCE LAP-HF-II Investigators
Baim Institute for Clinical Research · USBrigham and Women's Hospital · USCardiovascular Research Foundation · USHospital of the University of Pennsylvania · USUniversity Medical Center Groningen · NLAZ Sint-Jan · BEBaylor College of Medicine · USBoston University · USCapital Cardiology Associates · USCentre National de la Recherche Scientifique · FRCHU Dijon Bourgogne · FRCorvia Medical (United States) · USDermatologikum Hamburg · DEHamilton Health Sciences · CAHeinrich Heine University Düsseldorf · DEKerckhoff Klinik · DELake Michigan College · USLung Institute · USMayo Clinic · USMedical University of Graz · AT

Funding

HeartShare DeCODE-HF: Data translation center to Combine Omics, Deep phenotyping, and Electronic health records for Heart Failure subtypes and treatment targetsU54HL160273 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Abel N. Kho, Yuan Luo · 2021 to 2026
$19.0M
Study of Cardiac Mechanics in Systemic HypertensionR01HL107577 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SHAH, SANJIV J · 2011 to 2019
$4.1M
Machine learning for the automated identification and tracking of rare myocardial diseasesR01HL140731 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MACRAE, CALUM A., SHAH, SANJIV J · 2018 to 2021
$2.8M
HL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection FractionR01HL128526 · NHLBI · MAYO CLINIC ROCHESTER · PI BORLAUG, BARRY A. · 2016 to 2019
$2.4M
A multifaceted adaptive mobile application to promote self-management and improve outcomes in heart failureR01AG062582 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DORSCH, MICHAEL · 2020 to 2023
$2.1M
Multi-scale systems analysis of blood pressure control and hypertensionR01HL139813 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BEARD, DANIEL A · 2018 to 2021
$2.0M
Mayo Clinic HeartShare Clinical CenterU01HL160226 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug, Margaret M Redfield · 2021 to 2026
$1.8M
Precision Medicine for Dilated Cardiomyopathy—Novel Assessment of Cardiac Mechanics via Speckle Tracking Echocardiography to Identify Early PhenotypesR01HL149423 · NHLBI · OHIO STATE UNIVERSITY · PI HERSHBERGER, RAY E., KINNAMON, DANIEL DAVIS · 2019 to 2022
$1.6M
A Just-In-Time Adaptive Mobile Application Intervention To Reduce Sodium Intake And Blood Pressure In Hypertensive PatientsR61HL155498 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DORSCH, MICHAEL, NALLAMOTHU, BRAHMAJEE K · 2021 to 2021
$776k
British Heart Foundation RE/18/6/34217NHLBI NIH HHS R01 HL107577NHLBI NIH HHS R01 HL128526NHLBI NIH HHS R01 HL139813NHLBI NIH HHS R01 HL140731NHLBI NIH HHS R01 HL149423NHLBI NIH HHS R61 HL155498NHLBI NIH HHS U01 HL160226NHLBI NIH HHS U54 HL160273NIA NIH HHS R01 AG062582
6 · The paper itself

Abstract

backgroundIn REDUCE LAP-HF II (A Study to Evaluate the Corvia Medical, Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients With Heart Failure), implantation of an atrial shunt device did not provide overall clinical benefit for patients with heart failure with preserved or mildly reduced ejection fraction. However, prespecified analyses identified differences in response in subgroups defined by pulmonary artery systolic pressure during submaximal exercise, right atrial volume, and sex. Shunt implantation reduces left atrial pressures but increases pulmonary blood flow, which may be poorly tolerated in patients with pulmonary vascular disease (PVD). On the basis of these results, we hypothesized that patients with latent PVD, defined as elevated pulmonary vascular resistance during exercise, might be harmed by shunt implantation, and conversely that patients without PVD might benefit.

methodsREDUCE LAP-HF II enrolled 626 patients with heart failure, ejection fraction ≥40%, exercise pulmonary capillary wedge pressure ≥25 mm Hg, and resting pulmonary vascular resistance <3.5 Wood units who were randomized 1:1 to atrial shunt device or sham control. The primary outcome-a hierarchical composite of cardiovascular death, nonfatal ischemic stroke, recurrent HF events, and change in health status-was analyzed using the win ratio. Latent PVD was defined as pulmonary vascular resistance ≥1.74 Wood units (highest tertile) at peak exercise, measured before randomization.

resultsCompared with patients without PVD (n=382), those with latent PVD (n=188) were older, had more atrial fibrillation and right heart dysfunction, and were more likely to have elevated left atrial pressure at rest. Shunt treatment was associated with worse outcomes in patients with PVD (win ratio, 0.60 [95% CI, 0.42, 0.86];

conclusionsIn patients with heart failure with preserved or mildly reduced ejection fraction, the presence of latent PVD uncovered by invasive hemodynamic exercise testing identifies patients who may worsen with atrial shunt therapy, whereas those without latent PVD may benefit.

Indexed as

Cardiac CatheterizationHeart AtriaHeart FailureVascular DiseasesFemaleHumansMalePulmonary CirculationStroke VolumeTreatment Outcomeclinical trialheart failurehypertension, pulmonarylung diseasestherapeuticsvascular diseases

Identifiers

PMID35354306
PMCPMC9133195
OpenAlexW4221030674

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.